viewShield Therapeutics PLC

Shield Therapeutics - Notice of Results

RNS Number : 8030Y
Shield Therapeutics PLC
14 September 2020


Shield Therapeutics plc

("Shield" or the "Group" or the "Company")


Notice of Results

Analyst and Investor Briefings


London, UK, 14 September 2020: Shield Therapeutics plc (LSE: STX), a commercial stage, pharmaceutical company with a focus on addressing iron deficiency with its lead product Feraccru®/Accrufer® (ferric maltol), will announce its interim results for the six months ended 30 June 2020 on Wednesday 16 September 2020.


Analyst briefing

A briefing open to analysts will take place remotely via video conference call on Wednesday 16 September 2020 at 11.00am. If you would like the details of this call please contact Walbrook PR on shield@walbrookpr.com.


Investor briefing

Shield Therapeutics will be hosting a live online presentation open to all investors on Wednesday 16 September at 4.30pm. The Company is committed to providing an opportunity for all existing and potential investors to hear directly from management on the recent developments and additionally providing an update on the business.


The presentation will be hosted through the digital platform Investor Meet Company. Investors can sign up to Investor Meet Company for free and add to meet Shield Therapeutics plc via the following link:



For those investors who have already registered and added to meet the Company, they will automatically be invited.


Questions can be submitted pre-event via your Investor Meet Company dashboard or in real time during the presentation, via the "Ask a Question" function.  Whilst the Company may not be in a position to answer every question it receives, it will aim to address the most prominent within the confines of information already disclosed to the market through regulatory notifications. A recording of the presentation, a PDF of the slides used, and responses to the Q&A session will be available on the Investor Meet Company platform afterwards.


For further information please contact:


Shield Therapeutics plc


Tim Watts, CEO

+44 (0)20 7186 8500

Karen Chandler Smith, Investor Relations



Nominated Adviser and Joint Broker


Peel Hunt LLP


James Steel/Dr Christopher Golden

+44 (0)20 7418 8900


Joint Broker

finnCap Ltd     

Geoff Nash/Matt Radley/Alice Lane                                             



+44 (0)20 7220 0500



 Financial PR & IR Advisor


Walbrook PR

+44 (0)20 7933 8780 or shield@walbrookpr.com

Paul McManus/Lianne Cawthorne

+44 (0)7980 541 893 / +44 (0)7584 391 303




About Shield Therapeutics plc


Shield is a de-risked, specialty pharmaceutical company focused on commercialising its lead product, Feraccru®/Accrufer®, a novel, stable, non-salt based oral therapy for adults with iron deficiency with or without anaemia. Feraccru®/Accrufer® has been approved for use in the United States, European Union, UK and Switzerland and has exclusive IP rights until the mid-2030s. Feraccru is commercialised in the UK and Europe by Norgine B.V. and the Company is currently in the process of selecting a commercialisation partner for the US market.  Shield also has an exclusive licence agreement with Beijing Aosaikang Pharmaceutical Co., Ltd., for the development and commercialisation of Feraccru®/Accrufer® in China, Hong Kong, Macau and Taiwan. 


For more information, please visit www.shieldtherapeutics.com. Follow Shield on Twitter @ShieldTx



This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

Quick facts: Shield Therapeutics PLC

Price: -

Market: LSE
Market Cap: -

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...


Shield Therapeutics raise £25m to launch Accrufer in US 'offering...

Shield Therapeutics PLC's (LON:STX) Tim Watts is 'delighted' by successful raise of £25mln through a share placing and subscription at 30p to launch and market its Accrufer iron deficiency treatment in the US. He also plans to offer an open opportunity to existing shareholders is also being...

1 day, 9 hours ago

4 min read